Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2017 1
2018 1
2019 3
2020 3
2021 1
2022 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

8 results

Results by year

Filters applied: . Clear all
Page 1
Fondazione Italiana Linfomi (FIL) expert consensus on the use of intensity-modulated and image-guided radiotherapy for Hodgkin's lymphoma involving the mediastinum.
Filippi AR, Meregalli S, DI Russo A, Levis M, Ciammella P, Buglione M, Guerini AE, De Marco G, De Sanctis V, Vagge S, Ricardi U, Simontacchi G; Fondazione Italiana Linfomi (FIL) Radiotherapy Committee. Filippi AR, et al. Radiat Oncol. 2020 Mar 12;15(1):62. doi: 10.1186/s13014-020-01504-8. Radiat Oncol. 2020. PMID: 32164700 Free PMC article. Review.
Outcome of transformed follicular lymphoma worsens according to the timing of transformation and to the number of previous therapies. A retrospective multicenter study on behalf of Fondazione Italiana Linfomi (FIL).
Rusconi C, Anastasia A, Chiarenza A, Marcheselli L, Cavallo F, Rattotti S, Botto B, Ferrari A, Nassi L, Pagani C, Meli E, Arcaini L, Federico M, Rossi G; Fondazione Italiana Linfomi (FIL). Rusconi C, et al. Br J Haematol. 2019 May;185(4):713-717. doi: 10.1111/bjh.15816. Epub 2019 Feb 21. Br J Haematol. 2019. PMID: 30793297 Free article.
Minimal residual disease (MRD) in non-Hodgkin lymphomas: Interlaboratory reproducibility on marrow samples with very low levels of disease within the FIL (Fondazione Italiana Linfomi) MRD Network.
Della Starza I, Cavalli M, De Novi LA, Genuardi E, Mantoan B, Drandi D, Barbero D, Ciabatti E, Grassi S, Gazzola A, Mannu C, Agostinelli C, Piccaluga PP, Bomben R, Degan M, Gattei V, Guarini A, Foà R, Galimberti S, Ladetto M, Ferrero S, Del Giudice I; Fondazione Italiana Linfomi (FIL) MRD Network. Della Starza I, et al. Hematol Oncol. 2019 Oct;37(4):368-374. doi: 10.1002/hon.2652. Epub 2019 Aug 16. Hematol Oncol. 2019. PMID: 31325190
Prognostic impact of TP53 mutation in newly diagnosed diffuse large B-cell lymphoma patients treated in the FIL-DLCL04 trial.
Chiappella A, Diop F, Agostinelli C, Novo M, Nassi L, Evangelista A, Ciccone G, Di Rocco A, Martelli M, Melle F, Moia R, Motta G, Righi S, Santambrogio E, Tucci A, Balzarotti M, Ladetto M, Pileri SA, Gaidano G, Vitolo U; Fondazione Italiana Linfomi (FIL). Chiappella A, et al. Br J Haematol. 2022 Mar;196(5):1184-1193. doi: 10.1111/bjh.17971. Epub 2021 Dec 23. Br J Haematol. 2022. PMID: 34951009
Ficoll-hypaque separation vs whole blood lysis: Comparison of efficiency and impact on minimal residual disease analysis.
Genuardi E, Barbero D, Dogliotti I, Mantoan B, Drandi D, Gambella M, Zaccaria GM, Monitillo L, Della Starza I, Cavalli M, De Novi LA, Ciabatti E, Grassi S, Gazzola A, Mannu C, Del Giudice I, Galimberti S, Agostinelli C, Piccaluga PP, Ladetto M, Ferrero S; Fondazione Italiana Linfomi (FIL) MRD Network. Genuardi E, et al. Int J Lab Hematol. 2018 Apr;40(2):201-208. doi: 10.1111/ijlh.12766. Epub 2017 Dec 4. Int J Lab Hematol. 2018. PMID: 29205868
Nonpeghylated liposomal doxorubicin combination regimen (R-COMP) for the treatment of lymphoma patients with advanced age or cardiac comorbidity.
Rigacci L, Annibali O, Kovalchuk S, Bonifacio E, Pregnolato F, Angrilli F, Vitolo U, Pozzi S, Broggi S, Luminari S, Merli F, Spina M, Bolis S, Margiotta-Casaluci G, Scalzulli R, Cox C, Mamusa AM, Santoro A, Zinzani PL, Ferrari S, Gini G, Vigliotti ML, Mulè A, Flenghi L; Fondazione Italiana Linfomi (FIL). Rigacci L, et al. Hematol Oncol. 2020 Oct;38(4):478-486. doi: 10.1002/hon.2764. Epub 2020 Jul 9. Hematol Oncol. 2020. PMID: 32542788 Free PMC article.
Immunoglobulin kappa deleting element rearrangements are candidate targets for minimal residual disease evaluation in mantle cell lymphoma.
Della Starza I, De Novi LA, Cavalli M, Novelli N, Soscia R, Genuardi E, Mantoan B, Drandi D, Ferrante M, Monitillo L, Barbero D, Ciabatti E, Grassi S, Bomben R, Degan M, Gattei V, Galimberti S, Di Rocco A, Martelli M, Cortelazzo S, Guarini A, Foà R, Ladetto M, Ferrero S, Del Giudice I; Fondazione Italiana Linfomi (FIL) MRD Network. Della Starza I, et al. Hematol Oncol. 2020 Dec;38(5):698-704. doi: 10.1002/hon.2792. Epub 2020 Aug 28. Hematol Oncol. 2020. PMID: 32816326
Bexarotene as maintenance treatment after therapies other than skin-directed therapy in advanced-stage mycosis fungoides: a pilot study.
Pileri A, Fava P, Fuligni F, Gunnella S, Guglielmo A, Astrua C, Grandi V, Simontacchi G, Patrizi A, Quaglino P, Pimpinelli N; Lymphoma Italian Foundation (Fondazione Italiana Linfomi-FIL) - Cutaneous Lymphoma Task Force (Commissione Linfomi Cutanei). Pileri A, et al. J Eur Acad Dermatol Venereol. 2019 Oct;33(10):e367-e369. doi: 10.1111/jdv.15661. Epub 2019 May 27. J Eur Acad Dermatol Venereol. 2019. PMID: 31066930 No abstract available.